Iron out KRAS-driven cancer

被引：2
|
作者：
Lei, Guang [1 ,2 ,3 ]
Gan, Boyi [3 ]
机构：
[1] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF EXPERIMENTAL MEDICINE | 2022年 / 219卷 / 04期
关键词：
D O I：
10.1084/jem.20212166
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment modalities in KRAS-driven cancer
    Tyson, Darren R.
    Singh, Neetu
    Bhavar, Prashant K.
    Sarma, Partha Pratim
    Surampudi, Uday Kumar
    Katike, Sathish
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [2] KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
    Than, Minh T.
    O'Hara, Mark
    Stanger, Ben Z.
    Reiss, Kim A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1378 - 1388
  • [3] Cancer vaccines: Targeting KRAS-driven cancers
    Zhang, Ying
    Ma, Jin-An
    Zhang, Hai-Xia
    Jiang, Yu-Na
    Luo, Wen-Hao
    EXPERT REVIEW OF VACCINES, 2020, 19 (02) : 163 - 173
  • [4] Metabolic vulnerability of KRAS-driven cancer cells
    Foster, David A.
    MOLECULAR & CELLULAR ONCOLOGY, 2014, 1 (03):
  • [5] A one-two punch for KRAS-driven cancer
    Megan Cully
    Nature Reviews Drug Discovery, 2015, 14 : 600 - 600
  • [6] Targeting copper metabolism to defeat KRAS-driven colorectal cancer
    Aubert, Leo
    Nandagopal, Neethi
    Roux, Philippe P.
    MOLECULAR & CELLULAR ONCOLOGY, 2020, 7 (06)
  • [7] Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
    Wang, Dong
    Cong, Jingjing
    Fu, Binqing
    Zheng, Xiaohu
    Sun, Rui
    Tian, Zhigang
    Wei, Haiming
    CANCER LETTERS, 2020, 492 : 31 - 43
  • [8] A treatment strategy for KRAS-driven tumors
    Trang T. Mai
    Piro Lito
    Nature Medicine, 2018, 24 : 902 - 904
  • [9] Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer
    Takeda, Mitsunobu
    Yang, Zecheng
    Theardy, Madeline S.
    Sorokin, Alexey
    Coker, Oluwadara
    Chen, Shuaitong
    Vien, Long T.
    Bover, Laura
    Ying, Haoqiang
    Kopetz, Scott
    Yao, Wantong
    CANCER RESEARCH, 2024, 84 (17)
  • [10] Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer
    Mariluz Soula
    Gokhan Unlu
    Rachel Welch
    Aleksey Chudnovskiy
    Beste Uygur
    Vyom Shah
    Hanan Alwaseem
    Paul Bunk
    Vishvak Subramanyam
    Hsi-Wen Yeh
    Artem Khan
    Søren Heissel
    Hani Goodarzi
    Gabriel D. Victora
    Semir Beyaz
    Kıvanç Birsoy
    Nature, 2024, 633 (8029) : 451 - 458
12345